Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DOW INC.DOW · Entity 3233 | Director | April 09, 2020 | April 13, 2020 |
| DuPont de Nemours, Inc.DWDP · Entity 3297 | Director | July 01, 2018 | April 15, 2019 |
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director | April 30, 2026 | May 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DOW INC.
Report date April 09, 2020 · Filed April 13, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,158 |
Reported balance
After 2020-04-09 transaction · row 1
1 source rowRow 1 · 2020-04-09 · Grant · Acquired 5,061 · Balance 25,158 F1: Time vested restricted stock units to be settled in one installment of shares of common stock of the Issuer following the date of separation of the Reporting Person. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 627 |
Reported balance
Holding disclosure · report date 2020-04-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 627 |
Filing footnotes · ownership attribution and instrument terms
F1: Time vested restricted stock units to be settled in one installment of shares of common stock of the Issuer following the date of separation of the Reporting Person.
DuPont de Nemours, Inc.
Report date July 01, 2018 · Filed April 15, 2019 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 1,882 |
Reported balance
Holding disclosure · report date 2018-07-01 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 1,882 F1: This amendment is being filed solely to reflect an additional 1282 shares of Common Stock, which were inadvertently omitted from the Form 3 of the Reporting Person filed with the Securities and Exchange Commission on July 6, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: This amendment is being filed solely to reflect an additional 1282 shares of Common Stock, which were inadvertently omitted from the Form 3 of the Reporting Person filed with the Securities and Exchange Commission on July 6, 2018.
GILEAD SCIENCES, INC.
Report date April 30, 2026 · Filed May 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,202 |
Reported balance
After 2026-04-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-30 · Grant · Acquired 1,146 · Balance 27,202 F1: Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $130.84 · Expires 2036-04-30 | Direct | 4,884 |
Reported balance
After 2026-04-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-30 · Grant · Acquired 4,884 · Balance 4,884 F2: 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.
F2: 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
DOW CHEMICAL CO /DE/
Report date August 31, 2017 · Filed September 05, 2017
Section 16 reporting ended · disclosed 2017-09-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| CommonSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 1
1 source rowRow 1 · 2017-08-31 · Disposition to issuer · Disposed 47,475 · Balance 0 F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 (the "Merger Agreement"), by and among the Issuer, E. I. du Pont de Nemours and Company, DowDuPont Inc. (f/k/a Diamond-Orion HoldCo, Inc., "DowDuPont"), Diamond Merger Sub, Inc. and Orion Merger Sub, Inc, pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly-owned subsidiary of DowDuPont. In the Merger, each share of Issuer Common Stock, par value $2.50 per share, was exchanged for one share of common stock, par value $0.01 per share, of DowDuPont ("DowDuPont Common Stock"). The closing price of a share of Common Stock on August 31, 2017 (the last trading day prior to the effectiveness of the Merger) was $66.65, and the closing price of a share of DowDuPont common stock on September 1, 2017 (the effective date of the Merger) was $67.18. |
| CommonSEC Table I · non-derivative | IndirectBy Spouse | 0 |
Reported balance
After 2017-08-31 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2017-08-31 · Disposition to issuer · Disposed 600 · Balance 0 F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 (the "Merger Agreement"), by and among the Issuer, E. I. du Pont de Nemours and Company, DowDuPont Inc. (f/k/a Diamond-Orion HoldCo, Inc., "DowDuPont"), Diamond Merger Sub, Inc. and Orion Merger Sub, Inc, pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly-owned subsidiary of DowDuPont. In the Merger, each share of Issuer Common Stock, par value $2.50 per share, was exchanged for one share of common stock, par value $0.01 per share, of DowDuPont ("DowDuPont Common Stock"). The closing price of a share of Common Stock on August 31, 2017 (the last trading day prior to the effectiveness of the Merger) was $66.65, and the closing price of a share of DowDuPont common stock on September 1, 2017 (the effective date of the Merger) was $67.18. |
| Phantom Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-08-31 · Disposition to issuer · Disposed 4,638.237 · Balance 0 F3: Each phantom stock unit was the economic equivalent of one share of Common Stock of the Issuer. As a result of the Merger, the phantom stock units in respect of deferrals and associated earnings were automatically converted to the economic equivalent of one share of DowDuPont Common Stock. F2: The phantom stock units were to be delivered entirely in cash in ten annual installments beginning in January following retirement. As a result of the Merger, these phantom stock units were assumed by DowDuPont and will be delivered according to the same terms. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 (the "Merger Agreement"), by and among the Issuer, E. I. du Pont de Nemours and Company, DowDuPont Inc. (f/k/a Diamond-Orion HoldCo, Inc., "DowDuPont"), Diamond Merger Sub, Inc. and Orion Merger Sub, Inc, pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly-owned subsidiary of DowDuPont. In the Merger, each share of Issuer Common Stock, par value $2.50 per share, was exchanged for one share of common stock, par value $0.01 per share, of DowDuPont ("DowDuPont Common Stock"). The closing price of a share of Common Stock on August 31, 2017 (the last trading day prior to the effectiveness of the Merger) was $66.65, and the closing price of a share of DowDuPont common stock on September 1, 2017 (the effective date of the Merger) was $67.18.
F2: The phantom stock units were to be delivered entirely in cash in ten annual installments beginning in January following retirement. As a result of the Merger, these phantom stock units were assumed by DowDuPont and will be delivered according to the same terms.
F3: Each phantom stock unit was the economic equivalent of one share of Common Stock of the Issuer. As a result of the Merger, the phantom stock units in respect of deferrals and associated earnings were automatically converted to the economic equivalent of one share of DowDuPont Common Stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 30, 2026 Filed May 4, 2026 20:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 4,884 | $0.00 Strike: $130.84 | $0.00 |
DisclosureSEC source: 0001183680-26-000002 · wk-form4_1777927002.xml · derivative · entry 2 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,884 Underlying: Common Stock · 4,884 shares Expires 2036-04-30 F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026. Read SEC document |
| April 30, 2026 Filed May 4, 2026 20:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 1,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001183680-26-000002 · wk-form4_1777927002.xml · nonDerivative · entry 1 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,202 F1 · security: Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026. Read SEC document |
| May 07, 2025 Filed May 8, 2025 22:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 6,809 | $0.00 Strike: $98.90 | $0.00 |
DisclosureSEC source: 0001127602-25-013745 · form4.xml · derivative · entry 2 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,809 Underlying: Common Stock · 6,809 shares Expires 2035-05-07 F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 7, 2025. Read SEC document |
| May 07, 2025 Filed May 8, 2025 22:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 1,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013745 · form4.xml · nonDerivative · entry 1 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,056 F1 · security: Represents 1,516 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 7, 2025. Read SEC document |
| May 08, 2024 Filed May 9, 2024 21:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 12,648 | $0.00 Strike: $64.92 | $0.00 |
DisclosureSEC source: 0001127602-24-014834 · form4.xml · derivative · entry 2 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,648 Underlying: Common Stock · 12,648 shares Expires 2034-05-08 F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 8, 2024. Read SEC document |
| May 08, 2024 Filed May 9, 2024 21:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 2,310 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-014834 · form4.xml · nonDerivative · entry 1 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,540 F1 · security: Represents 2,310 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 8, 2024. Read SEC document |
| May 03, 2023 Filed May 4, 2023 23:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 10,173 | $79.45 Strike: $79.45 | $808,244.85 |
DisclosureSEC source: 0001127602-23-014593 · form4.xml · derivative · entry 2 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,173 Underlying: Common Stock · 10,173 shares Expires 2033-05-03 F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 3, 2023. Read SEC document |
| May 03, 2023 Filed May 4, 2023 23:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 1,887 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014593 · form4.xml · nonDerivative · entry 1 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,230 F1 · security: Represents 1,887 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 3, 2023. Read SEC document |
| May 05, 2022 Filed May 6, 2022 23:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 15,851 | $0.00 Strike: $61.35 | $0.00 |
DisclosureSEC source: 0001127602-22-013728 · form4.xml · derivative · entry 2 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,851 Underlying: Common Stock · 15,851 shares Expires 2032-05-05 F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately on the grant date of May 5, 2022. Read SEC document |
| May 05, 2022 Filed May 6, 2022 23:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 2,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013728 · form4.xml · nonDerivative · entry 1 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,343 F1 · security: Represents 2,444 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 5, 2022. Read SEC document |
| May 03, 2022 Filed May 4, 2022 00:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-013133 · form4.xml · derivative · entry 2 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,553 Underlying: Common Stock · 2,223 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 3, 2022. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 3, 2022. Read SEC document |
| May 03, 2022 Filed May 4, 2022 00:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-013133 · form4.xml · nonDerivative · entry 1 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,899 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 14,665 | $0.00 Strike: $67.45 | $0.00 |
DisclosureSEC source: 0001127602-21-016858 · form4.xml · derivative · entry 2 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,665 Underlying: Common Stock · 14,665 shares Expires 2031-05-12 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-016858 · form4.xml · derivative · entry 1 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,776 Underlying: Common Stock · 2,223 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units will vest on the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. F2 · derivative.expiration_date: 100% of the restricted stock units will vest on the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 06, 2021 Filed May 7, 2021 22:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,936 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-015954 · form4.xml · derivative · entry 2 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,553 Underlying: Common Stock · 1,936 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 6, 2021. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 6, 2021. Read SEC document |
| May 06, 2021 Filed May 7, 2021 22:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,936 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-015954 · form4.xml · nonDerivative · entry 1 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,676 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 06, 2020 Filed May 8, 2020 00:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 7,886 | $0.00 Strike: $77.47 | $0.00 |
DisclosureSEC source: 0001127602-20-015835 · form4.xml · derivative · entry 2 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,886 Underlying: Common Stock · 7,886 shares Expires 2030-05-06 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary from May 6, 2020 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 6, 2021 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 06, 2020 Filed May 8, 2020 00:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 1,936 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-015835 · form4.xml · derivative · entry 1 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,489 Underlying: Common Stock · 1,936 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 6, 2021, or the day immediately preceding the next regular annual stockholders meeting. F2 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 6, 2021, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 21:19 UTC | DOW INC. DOW · Entity 3233 | GrantCommon Stock | 5,061 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-006414 · doc4.xml · nonDerivative · entry 1 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,158 F1 · shares: Time vested restricted stock units to be settled in one installment of shares of common stock of the Issuer following the date of separation of the Reporting Person. Read SEC document |
| May 08, 2019 Filed May 10, 2019 21:40 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 2,270 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-018192 · form4.xml · derivative · entry 2 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,553 Underlying: Common Stock · 2,270 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 8, 2020, or the day immediately preceding the next regular annual stockholders meeting. F3 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 8, 2020, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 08, 2019 Filed May 10, 2019 21:40 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 11,848 | $0.00 Strike: $66.07 | $0.00 |
DisclosureSEC source: 0001127602-19-018192 · form4.xml · derivative · entry 1 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,848 Underlying: Common Stock · 11,848 shares Expires 2029-05-08 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary from May 8, 2019 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 8, 2020 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| April 11, 2019 Filed Apr 15, 2019 21:08 UTC | DOW INC. DOW · Entity 3233 | GrantCommon Stock | 3,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-006752 · doc4.xml · nonDerivative · entry 1 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,097 F1 · shares: Time vested restricted stock units to be settled in one installment of shares of common stock of the Issuer following the date of separation of the Reporting Person. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 01:49 UTC | DOW INC. DOW · Entity 3233 | OtherPhantom Stock Units · Derivative | 1,616 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-006417 · doc4.xml · derivative · entry 3 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,616 Underlying: Common Stock · 1,616 shares Expires not disclosed F3 · derivative.exercise_price: There is generally no conversion price for these phantom stock units. Each phantom stock unit is the equivalent of one share of common stock of the Issuer. F1 · kind: On April 1, 2019, the Issuer separated from DowDuPont Inc. by issuing a dividend of the Issuer's common stock as further described in the Information Statement filed as Exhibit 99.1 to Form 10 filed by the Issuer on March 8, 2019. F4 · derivative.exercise_date: Phantom stock units accrue under a compensation deferral election. Phantom stock units are payable in cash in lump sum or installments at the election of the Reporting Person, and do not carry an exercisable date or expiration date. F4 · derivative.expiration_date: Phantom stock units accrue under a compensation deferral election. Phantom stock units are payable in cash in lump sum or installments at the election of the Reporting Person, and do not carry an exercisable date or expiration date. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 01:49 UTC | DOW INC. DOW · Entity 3233 | OtherCommon Stock | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-006417 · doc4.xml · nonDerivative · entry 2 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 200 F1 · kind: On April 1, 2019, the Issuer separated from DowDuPont Inc. by issuing a dividend of the Issuer's common stock as further described in the Information Statement filed as Exhibit 99.1 to Form 10 filed by the Issuer on March 8, 2019. F2 · balance_after: Total includes one share of common stock of the Issuer received for every three shares of DowDuPont common stock in connection with the separation. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 01:49 UTC | DOW INC. DOW · Entity 3233 | OtherCommon Stock | 16,717 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-006417 · doc4.xml · nonDerivative · entry 1 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,717 F1 · kind: On April 1, 2019, the Issuer separated from DowDuPont Inc. by issuing a dividend of the Issuer's common stock as further described in the Information Statement filed as Exhibit 99.1 to Form 10 filed by the Issuer on March 8, 2019. F2 · balance_after: Total includes one share of common stock of the Issuer received for every three shares of DowDuPont common stock in connection with the separation. Read SEC document |
| April 01, 2019 Filed Apr 15, 2019 21:08 UTC Amendment | DOW INC. DOW · Entity 3233 | OtherCommon Stock | 627 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-006764 · doc4a.xml · nonDerivative · entry 1 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 627 F1 · kind: On April 1, 2019, the Issuer separated from DowDuPont Inc. by issuing a dividend of the Issuer's common stock as further described in the Information Statement filed as Exhibit 99.1 to Form 10 filed by the Issuer on March 8, 2019. F2 · shares: This amendment is being filed solely to reflect an additional 427 shares of Common Stock, which were inadvertently omitted from the Form 4 of the Reporting Person filed with the Securities and Exchange Commission on April 3, 2019. F3 · balance_after: Total includes one share of common stock of the Issuer received for every three shares of DowDuPont common stock in connection with the separation. Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 23:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 480 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-003501 · form4.xml · derivative · entry 2 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,283 Underlying: Common Stock · 480 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on January 31, 2019. F2 · derivative.expiration_date: 100% of the restricted stock units vested on January 31, 2019. Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 23:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 480 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-003501 · form4.xml · nonDerivative · entry 1 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 09, 2018 Filed May 11, 2018 23:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 2,283 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-017238 · form4.xml · derivative · entry 2 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,763 Underlying: Common Stock · 2,283 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 9, 2019, or the day immediately preceding the next regular annual stockholders meeting. F3 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 9, 2019, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 09, 2018 Filed May 11, 2018 23:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 9,496 | $0.00 Strike: $65.69 | $0.00 |
DisclosureSEC source: 0001127602-18-017238 · form4.xml · derivative · entry 1 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,496 Underlying: Common Stock · 9,496 shares Expires 2028-05-09 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary measured from May 9, 2018 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 9, 2019 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 21:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 480 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-003636 · form4.xml · derivative · entry 2 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480 Underlying: Common Stock · 480 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest on January 31, 2019 at the end of the first year of service. F3 · derivative.expiration_date: 100% of the restricted stock units will vest on January 31, 2019 at the end of the first year of service. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 21:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 2,119 | $0.00 Strike: $83.80 | $0.00 |
DisclosureSEC source: 0001127602-18-003636 · form4.xml · derivative · entry 1 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,119 Underlying: Common Stock · 2,119 shares Expires 2028-01-31 F1 · derivative.exercise_date: Options vest quarterly over the first year of service and will be fully vested on January 31, 2019. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 21:17 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | Disposition to issuerPhantom Stock Units · Derivative | 4,638.237 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001225208-17-014609 · doc4.xml · derivative · entry 3 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 4,638.237 shares Expires not disclosed F3 · price: Each phantom stock unit was the economic equivalent of one share of Common Stock of the Issuer. As a result of the Merger, the phantom stock units in respect of deferrals and associated earnings were automatically converted to the economic equivalent of one share of DowDuPont Common Stock. F2 · derivative.exercise_date: The phantom stock units were to be delivered entirely in cash in ten annual installments beginning in January following retirement. As a result of the Merger, these phantom stock units were assumed by DowDuPont and will be delivered according to the same terms. F2 · derivative.expiration_date: The phantom stock units were to be delivered entirely in cash in ten annual installments beginning in January following retirement. As a result of the Merger, these phantom stock units were assumed by DowDuPont and will be delivered according to the same terms. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 21:17 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | Disposition to issuerCommon | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-014609 · doc4.xml · nonDerivative · entry 2 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 F1 · kind: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 (the "Merger Agreement"), by and among the Issuer, E. I. du Pont de Nemours and Company, DowDuPont Inc. (f/k/a Diamond-Orion HoldCo, Inc., "DowDuPont"), Diamond Merger Sub, Inc. and Orion Merger Sub, Inc, pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly-owned subsidiary of DowDuPont. In the Merger, each share of Issuer Common Stock, par value $2.50 per share, was exchanged for one share of common stock, par value $0.01 per share, of DowDuPont ("DowDuPont Common Stock"). The closing price of a share of Common Stock on August 31, 2017 (the last trading day prior to the effectiveness of the Merger) was $66.65, and the closing price of a share of DowDuPont common stock on September 1, 2017 (the effective date of the Merger) was $67.18. F1 · price: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 (the "Merger Agreement"), by and among the Issuer, E. I. du Pont de Nemours and Company, DowDuPont Inc. (f/k/a Diamond-Orion HoldCo, Inc., "DowDuPont"), Diamond Merger Sub, Inc. and Orion Merger Sub, Inc, pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly-owned subsidiary of DowDuPont. In the Merger, each share of Issuer Common Stock, par value $2.50 per share, was exchanged for one share of common stock, par value $0.01 per share, of DowDuPont ("DowDuPont Common Stock"). The closing price of a share of Common Stock on August 31, 2017 (the last trading day prior to the effectiveness of the Merger) was $66.65, and the closing price of a share of DowDuPont common stock on September 1, 2017 (the effective date of the Merger) was $67.18. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 21:17 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | Disposition to issuerCommon | 47,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-014609 · doc4.xml · nonDerivative · entry 1 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 (the "Merger Agreement"), by and among the Issuer, E. I. du Pont de Nemours and Company, DowDuPont Inc. (f/k/a Diamond-Orion HoldCo, Inc., "DowDuPont"), Diamond Merger Sub, Inc. and Orion Merger Sub, Inc, pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly-owned subsidiary of DowDuPont. In the Merger, each share of Issuer Common Stock, par value $2.50 per share, was exchanged for one share of common stock, par value $0.01 per share, of DowDuPont ("DowDuPont Common Stock"). The closing price of a share of Common Stock on August 31, 2017 (the last trading day prior to the effectiveness of the Merger) was $66.65, and the closing price of a share of DowDuPont common stock on September 1, 2017 (the effective date of the Merger) was $67.18. F1 · price: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 (the "Merger Agreement"), by and among the Issuer, E. I. du Pont de Nemours and Company, DowDuPont Inc. (f/k/a Diamond-Orion HoldCo, Inc., "DowDuPont"), Diamond Merger Sub, Inc. and Orion Merger Sub, Inc, pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly-owned subsidiary of DowDuPont. In the Merger, each share of Issuer Common Stock, par value $2.50 per share, was exchanged for one share of common stock, par value $0.01 per share, of DowDuPont ("DowDuPont Common Stock"). The closing price of a share of Common Stock on August 31, 2017 (the last trading day prior to the effectiveness of the Merger) was $66.65, and the closing price of a share of DowDuPont common stock on September 1, 2017 (the effective date of the Merger) was $67.18. Read SEC document |
| May 12, 2017 Filed May 16, 2017 19:15 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | GrantCommon | 2,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009890 · doc4.xml · nonDerivative · entry 1 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,475 F1 · shares: Award of stock with transfer restrictions exempt under Rule 16b-3 Read SEC document |
| November 03, 2016 Filed Nov 7, 2016 21:09 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,050 | $0.00 Strike: $41.97 | $0.00 |
DisclosureSEC source: 0001225208-16-041263 · doc4.xml · derivative · entry 4 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 6,050 shares Expires 2017-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Award of stock with transfer restrictions under the 2003 Non-Employee Directors' Stock Incentive Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| November 03, 2016 Filed Nov 7, 2016 21:09 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | Tax withholdingCommon | 4,740 | $53.58 | $253,969.20 |
DisclosureSEC source: 0001225208-16-041263 · doc4.xml · nonDerivative · entry 2 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,725 Read SEC document |
| November 03, 2016 Filed Nov 7, 2016 21:09 UTC | DOW CHEMICAL CO /DE/ DOW · Entity 97744 | Exercise / conversionCommon | 6,050 | $41.97 | $253,918.50 |
DisclosureSEC source: 0001225208-16-041263 · doc4.xml · nonDerivative · entry 1 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.